Testosterone and mortality

Clinical Endocrinology

Volumn 81, Issue 4, 2014, Pages 477-487

  Muraleedharan, Vakkat ^a,b   Jones, Thomas Hugh ^a,b,c  

^a BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c KING S MILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPOGONADISM; KIDNEY DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; MORTALITY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; TESTOSTERONE;

EID: 84908102454     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12503     Document Type: Review

References (80)

1. Bhasin, S., Cunningham, G.R., Hayes, F.J. et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practise guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
2. Wang, C., Nieschlag, E., Swerdloff, R. et al. (2009) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. European Urology, 55, 121-130.
3. Rosner, W. & Vesper, H. (2010) Toward excellence in testosterone testing: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 95, 4542-4548.
4. Wu, F.C.W., Tajar, A., Beynon, J.M. et al. (2010) Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. New England Journal of Medicine, 363, 123-135.
5. Araujo, A.B., Esche, G.R., Kupelian, V. et al. (2007) Prevalence of symptomatic androgen deficiency in men. Journal of Clinical Endocrinology and Metabolism, 92, 4241-4247.
6. Stanworth, R.D. & Jones, T.H. (2008) Testosterone for the aging male; current evidence and recommended practice. Clinical Interventions in Aging, 3, 25-44.
7. Rao, P.M., Kelly, D.M. & Jones, T.H. (2013) Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews in Endocrinology, 9, 479-493.
8. Bojesen, A., Juul, S., Birkebaek, N.H. et al. (2006) Morbidity in Klinefelter Syndrome: a Danish register study based on hospital discharge diagnoses. Journal of Clinical Endocrinology and Metabolism, 91, 1254-1260.
9. Shores, M.M., Matsumoto, A.M., Sloan, K.L. et al. (2006) Low serum testosterone and mortality in male veterans. Archives in Internal Medicine, 166, 1660-1665.
10. Laughlin, G.A., Barrett-Connor, E. & Bergstrom, J. (2008) Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology and Metabolism, 93, 68-75.
11. Haring, R., Volzke, H., Steveling, A. et al. (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. European Heart Journal, 31, 1494-1501.
12. Vikan, T., Schirmer, H., Njolstad, I. et al. (2009) Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. European Journal of Endocrinology, 161, 435-442.
13. Tivesten, A., Vandenput, L., Labrie, F. et al. (2009) Low serum testosterone and estradiol predict mortality in elderly men. Journal of Clinical Endocrinology and Metabolism, 94, 2482-2488.
14. Menke, A., Guallar, E., Rohrmann, S. et al. (2010) Sex steroid hormone concentrations and risk of death in US men. American Journal of Epidemiology, 171, 583-592.
15. Hyde, Z., Norman, P.E., Flicker, L. et al. (2012) Low free testosterone predicts mortality from cardiovascular disease but not other causes: the health in men study. Journal of Clinical Endocrinology & Metabolism, 97, 179-189.
16. Khaw, K.-T., Dowsett, M., Folkerd, E. et al. (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation, 116, 2694-2701.
17. Lehtonen, A., Huupponen, R., Tuomilehto, J. et al. (2008) Serum testosterone but not leptin predicts mortality in elderly men. Age and Ageing, 37, 461-464.
18. Araujo, A.B., Kupelian, V. & Page, S.T. (2007) Sex steroids and all-cause and cause-specific mortality in men. Archives of Internal Medicine, 167, 1252-1260.
19. Smith, G.D., Ben-Shlomo, Y. & Beswick, A. (2005) Cortisol, testosterone, and coronary heart disease: prospective evidence from the caerphilly study. Circulation, 112, 332-340.
20. Haring, R., Teng, Z., Xanthakis, V. et al. (2013) Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clinical Endocrinology, 78, 629-634.
21. Araujo, A.B., Dixon, J.M., Suarez, E.A. et al. (2011) Endogenous testosterone and mortality in men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 96, 3007-3019.
22. Corona, G., Rastrelli, G., Monami, M. et al. (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology, 165, 687-701.
23. Yeap, B.B., Alfonso, H., Chubb, S.A.P. et al. (2013) In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Journal of Clinical Endocrinology and Metabolism, 99, E9-E18.
24. Pye, S.R., Huhtaniemi, I.T., Finn, J.D. et al. (2014) Late-onset hypogonadism and mortality in aging men. Journal of Endocrinology and Metabolism, 99, 1357-1366.
25. Lerchbaum, E., Pilz, S., Boehm, B.O. et al. (2012) Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clinical Endocrinology, 77, 475-483.
26. Kyriazis, J., Tzanakis, I., Stylianou, K. et al. (2011) Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrology Dialysis Transplantation, 26, 2971-2977.
27. Haring, R., Nauck, M., Volzke, H. et al. (2011) Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. American Journal of Nephrology, 33, 209-217.
28. Malkin, C.J., Pugh, P.J., Morris, P.D. et al. (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 96, 1821-1825.
29. Corona, G., Monami, M., Boddi, V. et al. (2010) Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. Journal of Sexual Medicine, 7, 1557-1564.
30. Jones, T.H. (2010) Testosterone deficiency: a risk factor for cardiovascular disease? Trends in Endocrinology and Metabolism, 21, 496-503.
31. Jones, T.H. & Saad, F. (2009) The effect of testosterone on risk factors for, and the mediators of, atherosclerotic process. Atherosclerosis, 207, 318-327.
32. English, K.M., Mandour, O., Steeds, R.P. et al. (2000) Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal, 21, 890-894.
33. Ponikowska, B., Jankowska, E.A., Maj, J. et al. (2010) Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. International Journal of Cardiology, 143, 343-348.
34. Militaru, C., Donoiu, I., Dracea, O. et al. (2010) Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiology Journal, 17, 249-253.
35. Ohlsson, C., Barrett-Connor, E., Bhasin, S. et al. (2011) High serum testosterone is associated with reduced risk of cardiovascular events in elderly men the MrOS (Osteoporotic Fractures in Men) study in Sweden. Journal of the American College of Cardiology, 58, 1674-1681.
36. Akishita, M., Hashimoto, M., Ohike, Y. et al. (2010) Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis, 210, 232-236.
37. Wang, X.-F., Wang, J.-H. & Li, J.-Y. (2010) Androgen deficiency in elderly men with systolic chronic heart failure. Journal of Geriatric Cardiology, 7, 138-142.
38. Ebrahim, S., Smith, G.D., May, M. et al. (2003) Shaving, coronary heart disease, and stroke - the caerphilly study. American Journal of Epidemiology, 157, 234-238.
39. Nettleship, J.E., Pugh, P.J., Channer, K.S. et al. (2007) Inverse relationship between serum levels of interleukin-1 b and testosterone in men with stable coronary artery disease. Hormone and Metabolic Research, 39, 366-371.
40. Malkin, C.J., Pugh, P.J., Jones, R.D. et al. (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. Journal of Clinical Endocrinology & Metabolism, 89, 3313-3318.
41. Muller, M., van den Beld, A.W., Bots, M.L. et al. (2004) Endogenous sex hormones and progression of atherosclerosis in elderly men. Circulation, 109, 2074-2079.
42. Tivesten, A., Mellstrom, D., Jutberger, H. et al. (2007) Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men - the MrOS study in Sweden. Journal of the American College of Cardiology, 50, 1070-1076.
43. Hak, E.A., Witteman, J.C.M., De Jong, F.H. et al. (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study. Journal of Clinical Endocrinology and Metabolism, 87, 3632-3639.
44. Levine, G.N., D'Amico, A.V., Berger, P. et al. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk. A science advisory from the American Heart Association, American Cancer Society, and American Urological Association Endorsed by the American Society for Radiation Oncology. Circulation, 121, 833-840.
45. Keating, N.L., O'Malley, A.J. & Smith, M.R. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448-4456.
46. Derweesh, I.H., DiBlasio, C.J., Kincade, M.C. et al. (2007) Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. British Journal of Urology International, 100, 1060-1065.
47. Tomlinson, J.W., Holden, N., Hills, R.K. et al. (2001) Association between premature mortality and hypopituitarism. Lancet, 357, 425-431.
48. Muraleedharan, V., Marsh, H., Kapoor, D. et al. (2013) Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169, 725-733.
49. Fleishman, S.B., Khan, H., Homel, P. et al. (2010) Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. Journal of Clinical Oncology, 28, 5054-5060.
50. Garcia, J.M., Li, H.L., Mann, D. et al. (2006) Hypogonadism in male patients with cancer. Cancer, 106, 2583-2591.
51. Vigano, A., Piccioni, M., Trutschnigg, B. et al. (2010) Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncology, 11, 679-684.
52. Debigaré, R., Marquis, K., Côté, C.H. et al. (2003) Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest, 124, 83-89.
53. Casaburi, R., Bhasin, S., Cosentino, L. et al. (2004) Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 170, 870-878.
54. Biskobing, D.M. (2002) COPD and osteoporosis. Chest, 121, 609-620.
55. Kalyani, R.R., Gavini, S. & Dobs, A.S. (2007) Male hypogonadism in systemic disease. Endocrinology and Metabolism Clinics of North America, 36, 333-348.
56. Semple, P.D.A., Beastall, G.H., Watson, W.S. et al. (1980) Serum testosterone depression associated with hypoxia in respiratory-failure. Clinical Science, 58, 105-106.
57. Reid, I.R., Wattie, D.J., Evans, M.C. et al. (1996) Testosterone therapy in glucocorticoid-treated men. Archives Internal Medicine, 156, 1173-1177.
58. Svartberg, J., Aasebo, U., Hjalmarsen, A. et al. (2004) Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respiratory Medicine, 98, 906-913.
59. Cerqueira, J., Moraes, M. & Glina, S. (2002) Erectile dysfunction: prevalence and associated variables in patients with chronic renal failure. International Journal of Impotence Research, 14, 65-71.
60. Palmer, B.F. (1999) Sexual dysfunction in uremia. Journal of the American Society of Nephrology, 10, 1381-1388.
61. Albaaj, F., Sivalingham, M., Haynes, P. et al. (2006) Prevalence of hypogonadism in male patients with renal failure. Postgraduate Medical Journal, 82, 693-696.
62. Palmer, B.F. (2004) Outcomes associated with hypogonadism in men with chronic kidney disease. Advances in Chronic Kidney Disease, 11, 342-347.
63. Carrero, J.J., Qureshi, A.R., Nakashima, A. et al. (2011) Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrology Dialysis Transplantation, 26, 184-190.
64. Carrero, J.J., Qureshi, A.R., Parini, P. et al. (2009) Low serum testosterone increases mortality risk among male dialysis patients. Journal of the American Society of Nephrology, 20, 613-620.
65. Gungor, O., Kircelli, F., Carrero, J.J. et al. (2010) Endogenous Testosterone and mortality in male hemodialysis patients: is it the result of aging? Clinical Journal of the American Society of Nephrology, 5, 2018-2023.
66. Shores, M.M., Smith, N.L., Forsberg, C.W. et al. (2012) Testosterone treatment and mortality in men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism, 97, 2050-2058.
67. Haddad, R.M., Kennedy, C.C., Caples, S.M. et al. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings, 82, 29-39.
68. Fernandez-Balsells, M.M., Murad, M.H., Lane, M. et al. (2010) Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 95, 2560-2575.
69. Carson III, C.C. & Rosano, G. (2012) Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. Journal of Sexual Medicine 9, 54-67.
70. Xu, L., Freeman, G., Cowling, B.J. et al. (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine, 11, 108. doi:10.1186/1741-7015-11-108.
71. Basaria, S., Coviello, A.D., Travison, T.G. et al. (2010) Adverse events associated with testosterone administration. New England Journal of Medicine, 363, 109-122.
72. Srinivas-Shankar, U., Roberts, S.A., Connolly, M.J. et al. (2010) Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology & Metabolism, 95, 639-650.
73. Soisson, V., Brailly-Tabard, S., Helmer, C. et al. (2013) A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas, 75, 282-288.
74. Vigen, R., O'Donnell, C.I., Baron, A. et al. (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310, 1829-1836.
75. Finkle, W.D., Greenland, S., Ridgeway, G.K. et al. (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 9, 1-7.
76. English, K.M., Steeds, R.P., Jones, T.H. et al. (2000) Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina - a randomized, double-blind, placebo-controlled study. Circulation, 102, 1906-1911.
77. Malkin, C.J., Pugh, P.J., West, J.N. et al. (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. European Heart Journal, 27, 57-64.
78. Caminiti, G., Volterrani, M., Iellamo, F. et al. (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. Journal of the American College of Cardiology, 54, 919-927.
79. Bojesen, A., Juul, S., Birkeback, N. et al. (2004) Increased mortality in Klinefelter's syndrome. Journal of Clinical Endocrinology and Metabolism, 89, 3830-3834.
80. Zitzmann, M., Faber, S. & Nieschlag, E. (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. Journal of Clinical Endocrinology and Metabolism, 91, 4335-4343.